| 1 |
34312098 | Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients. | 2022 Jan |
2 |
| 2 |
33720069 | Changes in the therapeutic landscape of oesophago-gastric cancers. | 2021 Jul 1 |
1 |
| 3 |
34710829 | Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells. | 2021 Dec 10 |
1 |
| 4 |
31918721 | Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. | 2020 Jan 9 |
1 |
| 5 |
32014926 | VDR Agonists Increase Sensitivity of MCF-7 and BT-474 Breast Cancer Cells to 5 FU. | 2020 Feb |
1 |
| 6 |
32235305 | Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry. | 2020 Mar 29 |
2 |
| 7 |
32727638 | Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2+ Breast Cancer Cells to 5-Fluorouracil. | 2020 Dec 10 |
2 |
| 8 |
30124494 | Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer. | 2019 Jan |
2 |
| 9 |
31019975 | Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo. | 2019 |
5 |
| 10 |
29451302 | Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis. | 2018 Jul 15 |
4 |
| 11 |
29845287 | Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2‑positive breast cancer. | 2018 Jul |
1 |
| 12 |
30056083 | Manuka honey synergistically enhances the chemopreventive effect of 5-fluorouracil on human colon cancer cells by inducing oxidative stress and apoptosis, altering metabolic phenotypes and suppressing metastasis ability. | 2018 Oct |
1 |
| 13 |
28160563 | Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer. | 2017 Apr 4 |
1 |
| 14 |
28494379 | Study on molecular structure, spectroscopic properties (FTIR and UV-Vis), NBO, QTAIM, HOMO-LUMO energies and docking studies of 5-fluorouracil, a substance used to treat cancer. | 2017 Sep 5 |
3 |
| 15 |
28850174 | Chemotherapy for advanced gastric cancer. | 2017 Aug 29 |
3 |
| 16 |
26810644 | Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms. | 2016 Jan 25 |
2 |
| 17 |
27626067 | Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. | 2016 Sep |
1 |
| 18 |
25744576 | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. | 2015 Apr |
2 |
| 19 |
25778705 | Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. | 2015 |
1 |
| 20 |
25871911 | Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine. | 2015 Aug |
1 |
| 21 |
25901146 | Targeted Delivery of 5-fluorouracil with Monoclonal Antibody Modified Bovine Serum Albumin Nanoparticles. | 2015 Spring |
3 |
| 22 |
26345461 | ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. | 2015 Sep 7 |
1 |
| 23 |
26623038 | Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model. | 2015 Sep |
3 |
| 24 |
24472145 | Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines. | 2014 Jan 29 |
1 |
| 25 |
23708506 | Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models. | 2013 Aug |
1 |
| 26 |
22222640 | HER2 testing in gastric cancer: a practical approach. | 2012 May |
1 |
| 27 |
22293713 | Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma. | 2012 May |
3 |
| 28 |
22534547 | Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression. | 2012 Nov-Dec |
1 |
| 29 |
22614071 | Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification. | 2012 Aug |
3 |
| 30 |
23422737 | Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. | 2012 Mar |
2 |
| 31 |
21712253 | Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. | 2011 Aug |
2 |
| 32 |
21985855 | Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T). | 2011 |
1 |
| 33 |
20238327 | Chemotherapy for advanced gastric cancer. | 2010 Mar 17 |
1 |
| 34 |
20682991 | Combination therapy of 5-fluorouracil with rapamycin for hormone receptor-negative human breast cancer. | 2010 Jul |
1 |
| 35 |
20811704 | The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer. | 2010 Oct |
1 |
| 36 |
21080742 | Trastuzumab: in HER2-positive metastatic gastric cancer. | 2010 Dec 3 |
1 |
| 37 |
21160270 | [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock]. | 2010 Dec |
1 |
| 38 |
19470942 | Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. | 2009 Jul 20 |
1 |
| 39 |
19885610 | 5-Fluorouracil combined with apigenin enhances anticancer activity through induction of apoptosis in human breast cancer MDA-MB-453 cells. | 2009 Dec |
4 |
| 40 |
17885815 | Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu. | 2008 Jan |
2 |
| 41 |
18082672 | The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. | 2008 Feb 15 |
3 |
| 42 |
18390970 | Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. | 2008 May 10 |
3 |
| 43 |
17200359 | Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. | 2007 Jan 1 |
1 |
| 44 |
18337622 | Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. | 2007 |
2 |
| 45 |
16137437 | HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. | 2005 Aug |
1 |
| 46 |
16243820 | Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. | 2005 Oct 15 |
1 |
| 47 |
16315942 | [Combination immunotherapy using autologous tumor-stimulated lymphocytes and trastuzumab (Herceptin) for the patients with recurrent breast cancer]. | 2005 Oct |
1 |
| 48 |
15640503 | Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy. | 2004 Dec |
2 |
| 49 |
12655533 | Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. | 2003 Apr 1 |
2 |
| 50 |
12761490 | HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. | 2003 May 22 |
1 |